PHAT

Phathom Pharmaceuticals Inc

Healthcare


Presented:08/15/2022
Price:$10.64
Cap:$0.42B
Current Price:$15.66
Cap:$1.07B

Presented

Date08/15/2022
Price$10.64
Market Cap$0.42B
Ent Value$0.21B
P/E RatioN/A
Book ValueN/A
Div Yield0%
Shares O/S39.18M
Ave Daily Vol293,150
Short Int12.99%

Current

Price$15.66
Market Cap$1.07B
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. Its product candidate vonoprazan is an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Publicly traded companies mentioned herein: Hercules Capital Inc (HTGC), Merck & Co Inc (MRK), Phathom Pharmaceuticals Inc (PHAT)

Highlights

The presenter is long shares of Phathom Pharmaceuticals Inc (PHAT), a $450MM market cap biotech company that is approaching commercialization of its first product Vonoprazan, a gastrointestinal (GI) acid suppressant that he views as a ~$100MM revenue opportunity for the company. PHAT is also working on a gastroesophageal reflux disease (GERD) program, which includes Erosive Esophagitis (EE) that is expected to receive approval early next year. Using conservative assumptions, he models out $490MM of peak EE sales, which exceeds the current market cap by itself.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.